OncLive TV

Benjamin Garmezy, MD, discusses key considerations for the selection of frontline treatment regimens in clear cell renal cell carcinoma.

Manish A. Shah, MD, discusses 5-year outcomes from KEYNOTE-590 of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.

Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.

Michael Choi, MD, discusses subsequent treatments for patients with relapsed/refractory CLL who progressed on a prior covalent BTK inhibitor.

Robin Jones, MD, MRCP, discusses the importance of communication between community and academic oncologists in cancer care.

Richard Kim, MD, discusses ongoing and planned research at Moffitt Cancer Center in patients with hepatocellular carcinoma.

Tycel Phillips, MD, discusses the potential advantages of treating patients with relapsed/refractory mantle cell lymphoma in the phase 3 GLOBRYTE trial.

Thomas Powles, MD, MBBS, MRCP, discusses the use of enfortumab vedotin plus pembrolizumab in urothelial carcinoma based on data from the KEYNOTE-A39 trial.

Viktor Gruenwald, MD, PhD, discusses key results from a post-hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma.

Adam M. Brufsky, MD, PhD, FACP, discusses the remaining questions following the FDA approval of capivasertib/fulvestrant in HR+/HER2- breast cancer.

David R. Wise, MD, PhD, discusses progress made in the treatment of patients with metastatic castration-resistant prostate cancer.

Nina D'Abreo, MD, discusses the evolution of antibody-drug conjugates in the treatment of patients with HER2-low or HER2-positive breast cancer.

Sumanta Kumar Pal, MD, FASCO, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.

Michael Choi, MD, discusses key differences between BTK degraders & BTK inhibitors in the management of relapsed/refractory chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses non-BCMA CAR T-cell therapies currently under investigation in multiple myeloma.

Sikander Ailawadhi, MD, shares considerations for the potential sequencing of bispecific antibodies and other BCMA-directed therapies in multiple myeloma.

Richard Kim, MD, discusses selecting between frontline immunotherapy-based regimens in patients with hepatocellular carcinoma.

Tycel Phillips, MD, discusses the rationale for the phase 3 GLOBRYTE trial examining glofitamab in patients with relapsed/refractory mantle cell lymphoma.

Alexey Danilov, MD, PhD, discusses how further research may address unmet needs in chronic lymphocytic leukemia or mantle cell lymphoma.

Srinivas K. Tantravahi, MBBS, MRCP, discusses the preliminary efficacy of selinexor in combination with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis, as seen in the phase 1 XPORT-MF-034 trial.

Patricia A. Possik, PhD, discusses the importance of efforts to improve diversity, equity, and inclusion in melanoma research.

Ariel Grajales-Cruz, MD, discusses real-world safety and efficacy outcomes with teclistamab in select patients with relapsed/refractory multiple myeloma.

John Mascarenhas, MD, discusses the potential advantages of utilizing selinexor with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Misako Nagasaka, MD, discusses key data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ non–small cell lung cancer.

Jane L. Meisel, MD, shares data from a study on communication challenges between providers and patients with metastatic breast cancer regarding TRAEs.

Joanna M. Rhodes, MD, MSCE, discusses the use of pirtobrutinib after covalent BTK inhibition in chronic lymphocytic leukemia or small lymphocytic lymphoma.

Evandro D. Bezerra, MD, discusses real-world outcomes associated with brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Ciara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.